Goethe University Frankfurt has spun out Vivlion to commercialise a library of the human genome that could drive the development of more Crispr therapies.
Germany-based biotechnology developer Vivlion has been spun out of Goethe University Frankfurt with the help of its technology transfer subsidiary Innovectis.
Vivlion has developed technology, dubbed 3Cs, that forms the basis of a large library cataloguing the location of individual genes within the human genome.
The approach has potentially far reaching consequences, as Crispr/Cas treatments have so far been held back by the difficulty in building large libraries of genes responsible for a certain action, such as cancer…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
